188 related articles for article (PubMed ID: 22964855)
1. Rapid re-expression of CD133 protein in colorectal cancer cell lines in vitro and in vivo.
Peickert S; Waurig J; Dittfeld C; Dietrich A; Garbe Y; Kabus L; Baumann M; Grade M; Ried T; Kunz-Schughart LA
Lab Invest; 2012 Nov; 92(11):1607-22. PubMed ID: 22964855
[TBL] [Abstract][Full Text] [Related]
2. CD133 expression is not selective for tumor-initiating or radioresistant cell populations in the CRC cell lines HCT-116.
Dittfeld C; Dietrich A; Peickert S; Hering S; Baumann M; Grade M; Ried T; Kunz-Schughart LA
Radiother Oncol; 2009 Sep; 92(3):353-61. PubMed ID: 19699546
[TBL] [Abstract][Full Text] [Related]
3. CD133 expression is not selective for tumor-initiating or radioresistant cell populations in the CRC cell line HCT-116.
Dittfeld C; Dietrich A; Peickert S; Hering S; Baumann M; Grade M; Ried T; Kunz-Schughart LA
Radiother Oncol; 2010 Mar; 94(3):375-83. PubMed ID: 20344822
[TBL] [Abstract][Full Text] [Related]
4. Microenvironmentally-driven Plasticity of CD44 isoform expression determines Engraftment and Stem-like Phenotype in CRC cell lines.
Dinger TF; Chen O; Dittfeld C; Hetze L; Hüther M; Wondrak M; Löck S; Eicheler W; Breier G; Kunz-Schughart LA
Theranostics; 2020; 10(17):7599-7621. PubMed ID: 32685007
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of CD44 and CD133 as cancer stem cell markers for colorectal cancer.
Wang C; Xie J; Guo J; Manning HC; Gore JC; Guo N
Oncol Rep; 2012 Oct; 28(4):1301-8. PubMed ID: 22895640
[TBL] [Abstract][Full Text] [Related]
6. The stem cell marker CD133 associates with enhanced colony formation and cell motility in colorectal cancer.
Elsaba TM; Martinez-Pomares L; Robins AR; Crook S; Seth R; Jackson D; McCart A; Silver AR; Tomlinson IP; Ilyas M
PLoS One; 2010 May; 5(5):e10714. PubMed ID: 20502714
[TBL] [Abstract][Full Text] [Related]
7. Upregulated CD133 expression in tumorigenesis of colon cancer cells.
Yang ZL; Zheng Q; Yan J; Pan Y; Wang ZG
World J Gastroenterol; 2011 Feb; 17(7):932-7. PubMed ID: 21412503
[TBL] [Abstract][Full Text] [Related]
8. Differential expression of CD133 based on microsatellite instability status in human colorectal cancer.
Park JJ; Kwon JH; Oh SH; Choi J; Moon CM; Ahn JB; Hong SP; Cheon JH; Kim TI; Kim H; Kim WH
Mol Carcinog; 2014 Feb; 53 Suppl 1():E1-10. PubMed ID: 23065858
[TBL] [Abstract][Full Text] [Related]
9. CD49f-positive cell population efficiently enriches colon cancer-initiating cells.
Haraguchi N; Ishii H; Mimori K; Ohta K; Uemura M; Nishimura J; Hata T; Takemasa I; Mizushima T; Yamamoto H; Doki Y; Mori M
Int J Oncol; 2013 Aug; 43(2):425-30. PubMed ID: 23708747
[TBL] [Abstract][Full Text] [Related]
10. Characterization and propagation of tumor initiating cells derived from colorectal liver metastases: trials, tribulations and a cautionary note.
James MI; Howells LM; Karmokar A; Higgins JA; Greaves P; Cai H; Dennison A; Metcalfe M; Garcea G; Lloyd DM; Berry DP; Steward WP; Brown K
PLoS One; 2015; 10(2):e0117776. PubMed ID: 25658706
[TBL] [Abstract][Full Text] [Related]
11. Salinomycin selectively targets 'CD133+' cell subpopulations and decreases malignant traits in colorectal cancer lines.
Dong TT; Zhou HM; Wang LL; Feng B; Lv B; Zheng MH
Ann Surg Oncol; 2011 Jun; 18(6):1797-804. PubMed ID: 21267784
[TBL] [Abstract][Full Text] [Related]
12. CD133(+)CXCR4(+) colon cancer cells exhibit metastatic potential and predict poor prognosis of patients.
Zhang SS; Han ZP; Jing YY; Tao SF; Li TJ; Wang H; Wang Y; Li R; Yang Y; Zhao X; Xu XD; Yu ED; Rui YC; Liu HJ; Zhang L; Wei LX
BMC Med; 2012 Aug; 10():85. PubMed ID: 22871210
[TBL] [Abstract][Full Text] [Related]
13. Cytometric profiling of CD133+ cells in human colon
carcinoma cell lines identifies a common core phenotype
and cell type-specific mosaics.
Gemei M; Di Noto R; Mirabelli P; Del Vecchio L
Int J Biol Markers; 2013 Sep; 28(3):267-73. PubMed ID: 23709346
[TBL] [Abstract][Full Text] [Related]
14. CD133+, CD166+CD44+, and CD24+CD44+ phenotypes fail to reliably identify cell populations with cancer stem cell functional features in established human colorectal cancer cell lines.
Muraro MG; Mele V; Däster S; Han J; Heberer M; Cesare Spagnoli G; Iezzi G
Stem Cells Transl Med; 2012 Aug; 1(8):592-603. PubMed ID: 23197865
[TBL] [Abstract][Full Text] [Related]
15. Human CD133-positive hematopoietic progenitor cells initiate growth and metastasis of colorectal cancer cells.
Zhang C; Zhou C; Wu XJ; Yang M; Yang ZH; Xiong HZ; Zhou CP; Lu YX; Li Y; Li XN
Carcinogenesis; 2014 Dec; 35(12):2771-7. PubMed ID: 25269803
[TBL] [Abstract][Full Text] [Related]
16. A gene signature distinguishing CD133hi from CD133- colorectal cancer cells: essential role for EGR1 and downstream factors.
Ernst A; Aigner M; Nakata S; Engel F; Schlotter M; Kloor M; Brand K; Schmitt S; Steinert G; Rahbari N; Koch M; Radlwimmer B; Weitz J; Lichter P
Pathology; 2011 Apr; 43(3):220-7. PubMed ID: 21436631
[TBL] [Abstract][Full Text] [Related]
17. Characterization of the conversion between CD133+ and CD133- cells in colon cancer SW620 cell line.
Feng JM; Miao ZH; Jiang Y; Chen Y; Li JX; Tong LJ; Zhang J; Huang YR; Ding J
Cancer Biol Ther; 2012 Dec; 13(14):1396-406. PubMed ID: 22954703
[TBL] [Abstract][Full Text] [Related]
18. The role of CD133 expression in the carcinogenesis and prognosis of patients with lung cancer.
Le H; Zeng F; Xu L; Liu X; Huang Y
Mol Med Rep; 2013 Nov; 8(5):1511-8. PubMed ID: 24008862
[TBL] [Abstract][Full Text] [Related]
19. Targeting CD133high Colorectal Cancer Cells In Vitro and In Vivo With an Asymmetric Bispecific Antibody.
Zhao L; Yang Y; Zhou P; Ma H; Zhao X; He X; Wang T; Zhang J; Liu Y; Zhang T
J Immunother; 2015; 38(6):217-28. PubMed ID: 26049545
[TBL] [Abstract][Full Text] [Related]
20. Side population rather than CD133(+) cells distinguishes enriched tumorigenicity in hTERT-immortalized primary prostate cancer cells.
Zhou J; Wang H; Cannon V; Wolcott KM; Song H; Yates C
Mol Cancer; 2011 Sep; 10():112. PubMed ID: 21917149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
